Catabasis, Duchenne UK announce partnership to evaluate edasalonexent in phase 2 non-ambulatory DMD trial

This article was originally published here

This exploratory Phase 2 trial, which is subject to the receipt of adequate funding, is designed to assess safety, pharmacokinetics and exploratory measures of function including cardiac, skeletal

The post Catabasis, Duchenne UK announce partnership to evaluate edasalonexent in phase 2 non-ambulatory DMD trial appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply